Search results
Found 59700 matches for
New analysis shows the lower range of the licensed dose of the most commonly used second-generation antidepressants achieves the optimal balance between efficacy, tolerability and acceptability in the acute treatment of adults with major depression.
Philip Wilkinson
S - Z
BMedSci BM BS (Nottingham), FRCPsych, Dip Obst (Auckland, New Zealand), Certificate in Cognitive Therapy (Oxford), ATCL, LGSMD, CELTA Philip Wilkinson - Honorary Senior Clinical Lecturer
Ilina Singh
S - Z
NEUROSCIENCE, ETHICS AND SOCIETY THEME LEAD Ilina Singh - Professor of Neuroscience & Society
Charles Newton
M - R
MBChB (UCT), MA (Oxford), MRCP (London), MD (UCT), FRCPCH Charles Newton - Cheryl & Reece Scott Professor of Psychiatry
Jennifer Rendell
M - R
MA(Oxon), DPhil, MBPsS Jennifer Rendell - Research Fellow & Deputy Director of Graduate Studies
Ksenija Yeeles
S - Z
DPhil, BSc (Hons) Ksenija Yeeles - Associate Research Group Leader, Research Member of Common Room Kellogg College
John Gallacher
F - L
PhD AFBPsS CPsychol FFPH John Gallacher - Professor of Cognitive Health; Director, Dementias Platform UK; Director, BrainWaves study of adolescent wellbeing and mental health
Paul Harrison
F - L
MA, BM. BCh, DM (Oxon), FRCPsych Paul Harrison - Professor of Psychiatry; Associate Head of Department (Research)
Rebecca Murphy
M - R
DClinPsych Rebecca Murphy - Senior Research Clinician and Hon Clinical Psychologist